1. Japan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Earth Corporation

Earth Corporation

TTSE:4985
4,940.00
JPY
+35.00
(+0.71%)
102.80BMarket Cap
Nov 09Next Earn
Earth Corporation
TSE:4985
(Tokyo Stock Exchange)

Recent

price

4,940.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
JPY
5,134.11
5,494.85
6,214.05
6,720.98
7,222.12
7,909.83
8,343.9
8,900.12
8,961.55
9,370
9,431.59
9,236.92
6,907.23
7,156.21
7,709.33
8,209.94
- -
Revenue per Share
170.38
164.64
85.21
147.85
84.42
57.69
166.58
109.19
-7.03
61.8
170.64
323.72
240.44
185.39
158.26
240
- -
Basic EPS, GAAP
257.9
409.83
92.25
249.36
187.71
-63.13
141.77
255.51
-89.42
377.42
1,072.45
86.66
-90.27
66.93
418.9
303.46
- -
Free Cash Flow per Basic Share
84.89
89.97
94.97
94.97
104.97
109.98
109.98
114.98
114.9
114.9
97.33
114.95
117.89
117.64
118.87
119.73
- -
Dividend per Share
1,973.59
2,039.51
2,048.28
2,151.5
2,192.86
2,151.83
2,154.93
2,225.31
1,989.93
1,978.84
2,507.61
2,720.35
2,846.03
3,007.53
3,162.25
3,429.18
3,696.49
Book Value per Share
1,944.73
2,016.09
1,247.05
1,428.79
1,477.37
1,522.84
1,554.2
1,271.83
1,189.55
1,329.24
2,223.38
2,526.34
2,603.32
2,611
2,821.16
3,083.92
3,359.93
Tangible Book Value per Share
20
20
20
20
20
20
20
20
20
20
21
22
22
22
22
22
22
Basic Weighted Avg Shares
103,478
110,974
125,499
135,737
145,858
159,739
168,505
179,738
181,104
189,527
196,045
203,785
152,339
158,344
169,278
179,182
- -
Sales/Revenue/Turnover
11.89
5.51
3.29
4.02
3.32
2.52
3.3
2.48
0.58
2.07
5.83
5.24
4.88
4.03
3.8
4.52
- -
Operating Margin (%)
1,381
1,565
3,179
3,451
3,253
3,907
4,187
5,288
5,849
6,588
6,183
5,372
4,281
4,237
4,570
4,754
- -
Depreciation Expense
3,434
3,325
1,721
2,986
1,705
1,165
3,364
2,205
-142
1,250
3,547
7,142
5,303
4,102
3,475
5,238
- -
Net Income, GAAP
41.04
43.44
56.78
48.32
60.89
61.4
40.67
45.64
84.23
53.71
47.06
32.25
30
32.81
36.21
30.75
- -
Effective Tax Rate (%)
3.32
3
1.37
2.2
1.17
0.73
2
1.23
-0.08
0.66
1.81
3.5
3.48
2.59
2.05
2.92
- -
Profit Margin (%)
24,632
28,867
16,477
17,161
14,946
11,952
10,719
4,099
-601
-2,287
15,863
21,718
20,621
16,677
17,196
21,385
26,958
Working Capital
190
130
4,167
2,826
7,006
8,030
7,838
10,354
6,809
3,550
2,218
1,200
- -
- -
- -
165
110
LT Debt
44,260
45,757
46,043
48,406
49,580
48,991
49,192
50,529
44,372
44,322
59,823
64,596
68,018
72,000
74,652
81,290
87,417
Total Equity
7.41
7.32
3.47
5.07
3.18
2.41
4.98
3.42
0.23
2.67
8.74
10.27
7.35
5.5
4.92
6.47
- -
Return on Invested Capital (%)
6.82
6.49
3
4.78
2.18
1.12
4.59
2.49
-0.82
1.5
5.02
10.3
7.2
5.02
3.94
5.87
- -
Return on Capital (%)
8.77
8.2
4.17
7.04
3.89
2.66
7.74
4.99
-0.33
3.11
7.44
12.39
8.64
6.34
5.13
7.29
- -
Return on Common Equity (%)

Capital Structure

JPY

•

in mil. unless spec.
Jun'24
Mar'26
Jun'26
ST Debt
7,000
- -
11,534
LT Borrowings
- -
- -
110
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
22
22
22
Market Capitalization
106,048
103,666
102,801

Working Capital

JPY

•

in mil. unless spec.
Jun'24
Mar'26
Jun'26
Total Current Assets
95,125
- -
101,718
Cash, Cash Equivalents & STI
23,602
- -
20,542
Accounts Receivable, Net
34,502
- -
39,354
Inventories
29,343
- -
31,399
Total Current Liabilities
74,687
- -
74,760
Payables & Accruals
- -
- -
- -
ST Debt
7,000
- -
11,534
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.75%
6.34%
8.89%
Free Cash Flow
-68.67%
4.63%
-28%
Net Income, GAAP
-66.03%
17.68%
50.73%
Sales/Revenue/Turnover
1.64%
-0.92%
5.85%
Total Cash Common Dividend
- -
5.68%
0.11%

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
42,049
55,046
- -
- -
169,278
2025
- -
- -
- -
- -
179,182
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
159.54
185.94
- -
- -
158.26
2025
- -
- -
- -
- -
240
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
118.87
2025
- -
- -
- -
- -
119.73
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Earth Corporation (4985.T), founded in 1892 and headquartered in Tokyo, Japan, manufactures, markets, imports and exports pharmaceutical products, quasi-drugs, medical tools and household products primarily in Japan and internationally through subsidiaries in Thailand, China, Vietnam and Malaysia. The company operates in household products and comprehensive environmental hygiene segments, offering pest control products including insecticides for flies, mosquitoes, cockroaches, mites, ants, hornets, spiders, rodents and other pests such as Earth Red fumigator, Earth No-mat liquid mosquito killer, Earth Jet spray, Earth Mosquito Coil, Saratect repellent, Gokiburi Hoi-Hoi cockroach traps, Goki Jet Pro, Black Cap bait and Earth Mushi Yoke Net EX; oral care items like Mondahmin mouthwash, Polident and Aquafresh; bath additives including Bath Roman, Onpo and Pirepara Earth; cleaning and hygiene products such as Sukki-ri!, air fresheners, deodorants and gardening supplies like Earth Garden; and pet supplies, fragrances and epidemic prevention chemicals. It provides environmental hygiene services and consulting for food and pharmaceutical factories. In recent developments, Earth Corporation completed a treasury share buyback in July 2024 acquiring 178,500 shares for 879 million yen, transferred to the Tokyo Stock Exchange Prime Market in 2022, acquired the BARTH brand business from TWO Inc. in 2023, released Gokish in 2024 and acquired PROTOLEAF, Inc. as a subsidiary in 2025; earlier changes include partnerships with Haleon Japan for oral care brands and entry into capital and business alliance with Taiko Pharmaceutical in 2016.